Hans Nissbrandt
Hans Nissbrandt
Professor, Dept of Pharmacology, Univ of Gothenburg
Verified email at
Cited by
Cited by
The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: a new role for mesolimbic GLP-1 receptors
SL Dickson, RH Shirazi, C Hansson, F Bergquist, H Nissbrandt, ...
Journal of Neuroscience 32 (14), 4812-4820, 2012
l‐DOPA‐induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson’s disease: temporal and quantitative relationship to the expression of …
HS Lindgren, DR Andersson, S Lagerkvist, H Nissbrandt, MA Cenci
Journal of neurochemistry 112 (6), 1465-1476, 2010
The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine
O Blomqvist, JA Engel, H Nissbrandt, B Söderpalm
European journal of pharmacology 249 (2), 207-213, 1993
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism
V Francardo, F Bez, T Wieloch, H Nissbrandt, K Ruscher, MA Cenci
Brain 137 (7), 1998-2014, 2014
Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease
V Francardo, A Recchia, N Popovic, D Andersson, H Nissbrandt, ...
Neurobiology of disease 42 (3), 327-340, 2011
The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease
CM Lill, A Rengmark, L Pihlstrøm, I Fogh, A Shatunov, PM Sleiman, ...
Alzheimer's & Dementia 11 (12), 1407-1416, 2015
Association of Nrf2-encoding NFE2L2 haplotypes with Parkinson's disease
M von Otter, S Landgren, S Nilsson, D Celojevic, P Bergström, ...
BMC medical genetics 11, 1-9, 2010
GABAB‐Receptor activation alters the firing pattern of dopamine neurons in the rat substantia nigra
G Engberg, T Kling‐Petersen, H Nissbrandt
Synapse 15 (3), 229-238, 1993
Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder
M Landén, H Nissbrandt, C Allgulander, K Sörvik, C Ysander, E Eriksson
Neuropsychopharmacology 32 (1), 153-161, 2007
Supportive evidence for 11 loci from genome-wide association studies in Parkinson's disease
L Pihlstrøm, G Axelsson, KA Bjørnarå, N Dizdar, C Fardell, L Forsgren, ...
Neurobiology of aging 34 (6), 1708. e7-1708. e13, 2013
GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality
RH Anderberg, JE Richard, C Hansson, H Nissbrandt, F Bergquist, ...
Psychoneuroendocrinology 65, 54-66, 2016
Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacta, pars reticulata, and striatum
H Nissbrandt, E Sundström, G Jonsson, S Hjorth, A Carlsson
Journal of neurochemistry 52 (4), 1170-1182, 1989
The stomach-derived hormone ghrelin increases impulsive behavior
RH Anderberg, C Hansson, M Fenander, JE Richard, SL Dickson, ...
Neuropsychopharmacology 41 (5), 1199-1209, 2016
Interaction of polymorphisms in the genes encoding interleukin‐6 and estrogen receptor beta on the susceptibility to Parkinson's disease
A Håkansson, L Westberg, S Nilsson, S Buervenich, A Carmine, ...
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 133 …, 2005
Somatodendritic dopamine release in rat substantia nigra influences motor performance on the accelerating rod
F Bergquist, HN Shahabi, H Nissbrandt
Brain research 973 (1), 81-91, 2003
PITX3 polymorphism is associated with early onset Parkinson's disease
O Bergman, A Håkansson, L Westberg, K Nordenström, AC Belin, ...
Neurobiology of aging 31 (1), 114-117, 2010
Pharmacologically induced cessation of burst activity in nigral dopamine neurons: significance for the terminal dopamine efflux
H Nissbrandt, A Elverfors, G Engberg
Synapse 17 (4), 217-224, 1994
Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain
E Eriksson, G Engberg, O Bing, H Nissbrandt
Neuropsychopharmacology 20 (3), 287-296, 1999
Genetic associations of Nrf2-encoding NFE2L2 variants with Parkinson’s disease–a multicenter study
M von Otter, P Bergström, A Quattrone, EV De Marco, G Annesi, ...
BMC medical genetics 15 (1), 1-13, 2014
Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites; effects on locomotor activity, dopaminergic neurotransmission and firing rate of nigral dopamine …
G Engberg, T Elebring, H Nissbrandt
Journal of Pharmacology and Experimental Therapeutics 259 (2), 841-847, 1991
The system can't perform the operation now. Try again later.
Articles 1–20